Hybio Pharmaceutical Co., Ltd. (Pingshan Factory): FDA NDC listings

Does Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) list GLP-1 drug products with FDA?

Yes. FDA’s NDC Directory files, read Nov 15, 2026, list 24 products naming liraglutide, retatrutide, semaglutide and tirzepatide under the labeler name “Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)”, in these marketing categories: BULK INGREDIENT (21); ANDA (3). A listing is the labeler’s own submission; FDA says it does not indicate that FDA has verified the information or that the product is FDA-approved.

GLP-1 listings
24
Marketing categories
BULK INGREDIENT (21); ANDA (3)
Drugs named
Liraglutide, Retatrutide, Semaglutide, Tirzepatide
Marketing start dates
Dec 1, 2021 to Mar 13, 2025

This page exists because the labeler has 2 or more compounded or bulk ingredient GLP-1 listings in FDA’s NDC files and no other page here under the same name. FDA’s NDC files give a labeler name, not an address or FEI number, so this index has not tied this labeler to any FDA inspection, letter or import record.

Listings

14403-0009Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 1, 2021None givenDec 31, 2026Unfinished drugs
14403-0009Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 1, 2021None givenDec 31, 2026Unfinished drugs
14403-0009Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTNov 20, 2024None givenDec 31, 2026Unfinished drugs
14403-0009Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 18, 2024None givenDec 31, 2026Unfinished drugs
14403-0009Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 18, 2024None givenDec 31, 2026Unfinished drugs
14403-0009Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 18, 2024None givenDec 31, 2026Unfinished drugs
14403-0009Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 18, 2024None givenDec 31, 2026Unfinished drugs
14403-0009Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 18, 2024None givenDec 31, 2026Unfinished drugs
14403-0021Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 19, 2024None givenDec 31, 2026Unfinished drugs
14403-0021Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 19, 2024None givenDec 31, 2026Unfinished drugs
14403-0021Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTMar 13, 2025None givenDec 31, 2026Unfinished drugs
14403-0022Not givenRetatrutidePOWDERNot given1 g/gBULK INGREDIENTFeb 26, 2025None givenDec 31, 2026Unfinished drugs
14403-0022Not givenRetatrutidePOWDERNot given1 g/gBULK INGREDIENTFeb 26, 2025None givenDec 31, 2026Unfinished drugs
14403-0022Not givenRetatrutidePOWDERNot given1 g/gBULK INGREDIENTFeb 26, 2025None givenDec 31, 2026Unfinished drugs
14403-0022Not givenRetatrutidePOWDERNot given1 g/gBULK INGREDIENTFeb 26, 2025None givenDec 31, 2026Unfinished drugs
14403-0022Not givenRetatrutidePOWDERNot given1 g/gBULK INGREDIENTFeb 26, 2025None givenDec 31, 2026Unfinished drugs
14403-0022Not givenRetatrutidePOWDERNot given1 g/gBULK INGREDIENTFeb 26, 2025None givenDec 31, 2026Unfinished drugs
14403-0018Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTJun 28, 2024None givenDec 31, 2026Unfinished drugs
14403-0017Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJun 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0020Not givenTirzepatidePOWDERNot given1 mg/mgBULK INGREDIENTJun 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0020Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJun 26, 2024None givenDec 31, 2026Unfinished drugs
14403-3400
ANDA215503
LiraglutideLiraglutideINJECTION, SOLUTIONSUBCUTANEOUS18 mg/3mLANDAJun 21, 2024None givenDec 31, 2026Finished drugs
14403-3400
ANDA215503
LiraglutideLiraglutideINJECTION, SOLUTIONSUBCUTANEOUS18 mg/3mLANDADec 24, 2024None givenDec 31, 2026Finished drugs
14403-3400
ANDA215503
LiraglutideLiraglutideINJECTION, SOLUTIONSUBCUTANEOUS18 mg/3mLANDADec 24, 2024None givenDec 31, 2026Finished drugs

FDA’s own words on the NDC Directory page (content current as of Mar 4, 2026):

Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved. The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file. Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law. Inclusion in the NDC Directory or assignment of an NDC number does not mean a product is a drug as defined by federal law.

All GLP-1 NDC listings.

This page restates listings from FDA’s NDC Directory files as FDA publishes them. A listing is the labeler’s own submission to FDA, not an FDA approval and not a finding by this site, and it says nothing about inspections or enforcement. Follow the source link for FDA’s files. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.